GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 274 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 274 shares of the business’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $66.60, for a total value of $18,248.40. Following the completion of the sale, the chief financial officer now directly owns 44,951 shares of the company’s stock, valued at $2,993,736.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Kevin Feeley also recently made the following trade(s):

• On Monday, September 9th, Kevin Feeley sold 895 shares of GeneDx stock. The shares were sold at an average price of $33.33, for a total value of $29,830.35.
• On Tuesday, September 3rd, Kevin Feeley sold 262 shares of GeneDx stock. The shares were sold at an average price of $31.71, for a total value of $8,308.02.

GeneDx Price Performance

Shares of NASDAQ:WGS traded down $1.51 during trading on Thursday, hitting $81.69. 781,807 shares of the stock were exchanged, compared to its average volume of 438,132. The company has a fifty day moving average price of $45.65 and a two-hundred day moving average price of $32.42. The company has a market cap of $2.20 billion, a PE ratio of -26.75 and a beta of 2.32. The company has a current ratio of 2.38, a quick ratio of 2.22 and a debt-to-equity ratio of 0.27. GeneDx Holdings Corp. has a 12-month low of $1.16 and a 12-month high of $89.11.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.15. The business had revenue of $70.51 million for the quarter, compared to analyst estimates of $58.90 million. GeneDx had a negative return on equity of 22.71% and a negative net margin of 48.21%. On average, analysts forecast that GeneDx Holdings Corp. will post -0.75 EPS for the current year.

Institutional Investors Weigh In On GeneDx

Institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. purchased a new stake in GeneDx in the 3rd quarter valued at approximately $604,000. Palumbo Wealth Management LLC purchased a new stake in GeneDx in the 3rd quarter valued at approximately $287,000. Precision Wealth Strategies LLC purchased a new stake in GeneDx in the 3rd quarter valued at approximately $364,000. Raymond James & Associates purchased a new stake in GeneDx in the 3rd quarter valued at approximately $8,090,000. Finally, CWM LLC purchased a new stake in GeneDx in the 3rd quarter valued at approximately $89,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on WGS. TD Cowen boosted their price target on GeneDx from $46.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. The Goldman Sachs Group boosted their price target on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research report on Wednesday. BTIG Research boosted their price target on GeneDx from $35.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. Wells Fargo & Company boosted their price target on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday. Finally, Craig Hallum boosted their target price on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, GeneDx has a consensus rating of “Moderate Buy” and an average price target of $59.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.